Ivry-sur-Seine, France, January 25, 2011 - EyeBrain, a developer of medical devices for the early diagnosis of neurological diseases, today announced that its eye-tracking system (Mobile Eye Brain Tracker or Mobile EBT) is now available on the market for the detection of Parkinson-plus diseases. The device has already been used on around 100 patients to test for these syndromes. Results have shown that eye movements provide a more accurate early diagnosis than traditional clinical examinations.
The company’s device is currently the only medical device to offer early diagnosis for a number of neurological diseases based on eye movements of patients. Furthermore, the Mobile EBT is non-invasive and costs less than regularly used imaging techniques, such as MRI or x-rays. It was developed in conjunction with La Pitié-Salpêtrière neurology team in Paris.
Parkinson-plus syndromes are a group of neurodegenerative diseases featuring the classical features of Parkinson’s with additional features that distinguish them from simple idiopathic Parkinson’s disease. They represent 15 per cent of Parkinson syndromes, and they are usually more rapidly progressive and less likely to respond to anti-parkinsonian medication than Parkinson’s disease. As these disorders are very difficult to diagnose at an early stage, neurologists usually wait for a minimum of two years before they can provide a final diagnosis.
The Mobile EBT device however offers the earlier detection of diseases, and can help distinguish between various Parkinson-plus syndromes, like progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), as well as multiple system atrophy (MSA). The device also allows monitoring of the progression of the disease in patients, and can be used for example during clinical trials.
Several brain areas are known to be involved in eye movements, and when a parameter of eye movement is abnormal, it could indicate dysfunction in the corresponding brain area. According to a study done by EyeBrain, to be published in 2011, eye movement tests provide a better basis for final diagnosis than traditional neurological examination of supranuclear palsy (PSP), the most frequent Parkinson-plus syndrome.
The Mobile EBT has been available in France, Belgium and Luxembourg since June 2010, and is expected to be launched soon in the UK, Ireland and European Nordic countries. It is already CE-marked for Europe. EyeBrain’s production capacity is about fifty devices a year and can be easily upgraded.
“Our Mobile EBTs are fully integrated and normalized systems that can handle the entire clinical examination from stimuli display to eye-movement capture and to data analysis and interpretation,” said Serge Kinkingnehun, Founder, CEO and Scientific Director of EyeBrain. “Our experience with many users has been excellent so far, and we look forward to seeing continuing success in speeding up the diagnosis for patients suffering from a number of neurological diseases.”
“We are delighted that many key opinion leaders in oculomotricity are also supporting us, alongside the Hospital de la Pitié-Salpêtrière with whom we jointly designed the system,” he added.
“The EBT provides real support to our work at diagnosing Parkinson-plus diseases, which are usually very difficult to detect, especially at an early stage,” said Dr. Bertrand Gaymard, neurologist, Hôpital Pitié-Salpêtrière, AP-HP (Paris). “With the help of this new system, we can also keep track of the development of different syndromes, which also helps our scientific work significantly.”
About EyeBrain
EyeBrain develops and manufactures medical devices for the early diagnosis of neurological diseases. EyeBrain tools are based on oculomotricity. The recording and analysis of eye movements using sophisticated proprietary algorithms allows the testing of specific areas of the brain. The speed and accuracy of EyeBrain’s technology represents a true breakthrough in the diagnosis of neurological diseases. For the first time, clinicians can complete a standard clinical examination in 20 minutes at a lower cost than that of imaging techniques such as MRI or x-rays. EyeBrain devices are also non-invasive as opposed to other frequently used tests such as lumbar puncture or blood tests.
The Mobile Eye Brain Tracker (Mobile EBT) provides a complete solution including a helmet, a computer and two screens plus the software needed for stimulation and analysis. Used as part of normal clinical routine, the Mobile EBT can provide valuable help in early characterization of the Parkinson-plus diseases (multiple system atrophy or MSA, progressive supranuclear palsy or PSP). EyeBrain is also working on the diagnosis of multiple sclerosis.
EyeBrain has obtained an impressive range of regulatory approvals. Mobile EBT is the first device of its kind in the world to have obtained CE marking, the company has received ISO 9001 and ISO 13485 certifications and the oculomotricity examination is reimbursed by French social security.
Founded in 2008, EyeBrain is based in the Paris region and currently has 15 employees. The company raised EUR 1.2 million in 2009 from CapDecisif and G1J and is already generating revenues through sales of its device. The company has collaboration agreements with Inserm, the CNRS, AP-HP, the Paris Descartes University and the ICM (Brain and Spinal Cord Institute). For further information: http://www.eye-brain.com
Lynne Chapman ANDREW LLOYD & ASSOCIATES http://www.ala.com lynne@ala.com
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION
